Myelolipoma After Infliximab Treatment for Crohn's Disease
Kevin Cesa1,2, Elaine Leonard Puppa1, Katayoun Eslami1
1Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Maryland, Baltimore, MD.
ACG Case Reports Journal
|July 5, 2022
Summary
A rare pelvic mass, myelolipoma, was found in a Crohn's disease patient on infliximab. This is the first reported case of myelolipoma in an immunosuppressed patient receiving infliximab therapy.
Area of Science:
- Gastroenterology
- Oncology
- Immunology
Background:
- Crohn's disease is a chronic inflammatory condition often treated with immunosuppressive therapies.
- Infliximab is a tumor necrosis factor-alpha inhibitor commonly used for Crohn's disease management.
- Pelvic masses can cause significant complications, including vascular compression.
Observation:
- A 20-year-old woman with Crohn's disease on infliximab therapy presented with lower extremity swelling.
- Imaging revealed an enlarging pelvic mass compressing the common iliac vein.
- Pathological examination confirmed the mass as a myelolipoma.
Findings:
- This case represents the first documented instance of a myelolipoma in a patient undergoing immunosuppression with infliximab.
- The pelvic myelolipoma caused symptomatic iliac vein compression.
Implications:
- This finding suggests a potential, albeit rare, association between infliximab-induced immunosuppression and myelolipoma development.
- Further research is warranted to explore the potential link between immunosuppressive therapy and myelolipoma formation.
- Clinicians should consider rare pelvic masses in patients with inflammatory bowel disease on immunosuppressants presenting with unexplained symptoms.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
227
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
227
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
260
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
260
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
198
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
198
01:30Inflammatory Bowel Disease II: Crohn's Disease
369
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
369
01:29Drugs for Treatment of Ulcerative Colitis in IBD
230
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
230
01:29Inflammatory Bowel Disease IV: Pharmacological Management
176
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
176